Bimekizumab

Extended indication	Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Bimekizumab
Domain	Chronic immune diseases
Reason of inclusion	Indication extension
Main indication	Rheumatism
Extended indication	Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
Proprietary name	Bimzelx
Manufacturer	UCB
Portfolio holder	Incyte
Mechanism of action	Interleukin inhibitor
Route of administration	Subcutaneous
Therapeutical formulation	Injection
Budgetting framework	Intermural (MSZ)
Additional remarks	Bimekizumab is a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. Vermoedelijk intramurale bekostiging vanwege het feit dat het een biological is.

Type of trajectory	Normal trajectory
Submission date	September 2022
Expected Registration	July 2023
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet

There is currently nothing known about the expected patient volume.

Cost	15,000.00 - 20,000.00
References	Farmacotherapeutisch kompas
Additional remarks	Bimzelx, 1 ml injectievloeistof 160 mg/ml: € 1.202,27. Op basis van inschattingen van andere biologicals met dezelfde indicatie is de verwachting dat bimekizumab €15.000-€20.000 zal gaan kosten.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.